Influencing Factors and Prognostic Value of ¹⁸F-FDG PET/CT Metabolic and Volumetric Parameters in Non-Small Cell Lung Cancer

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Slotman BJ, Senan S. Radiotherapy in small-cell lung cancer: lessons learned and future directions. Int J Radiat Oncol Biol Phys. 2011;79(4):998–1003. doi:10.1016/j.ijrobp.2010.10.039
   PubMed Web of Science ®Google Scholar
• Duma N, Santana-Davila R, Molina JR. Non-Small Cell Lung Cancer: epidemiology, Screening, Diagnosis, and Treatment. Mayo Clin Proce. 2019;94(8):1623–1640. doi:10.1016/j.mayocp.2019.01.013
   PubMed Web of Science ®Google Scholar
• Brainard J, Farver C. The diagnosis of non-small cell lung cancer in the molecular era. Modern Pathol. 2019;32(Suppl 1):16–26. doi:10.1038/s41379-018-0156-x
   PubMed Web of Science ®Google Scholar
• Wang C, Wang Z, Zhao T, et al. Optical molecular imaging for tumor detection and image-guided surgery. Biomaterials. 2018;157:62–75. doi:10.1016/j.biomaterials.2017.12.002
   PubMed Web of Science ®Google Scholar
• Abrantes AM, Pires AS, Monteiro L, et al. Tumour functional imaging by PET. Biochimica et biophysica acta Mol dis. 2020;1866(6):165717. doi:10.1016/j.bbadis.2020.165717
   PubMed Web of Science ®Google Scholar
• Valladares A, Beyer T, Rausch I. Physical imaging phantoms for simulation of tumor heterogeneity in PET, CT, and MRI: an overview of existing designs. Med Phys. 2020;47(4):2023–2037. doi:10.1002/mp.14045
   PubMed Web of Science ®Google Scholar
• Riola-Parada C, García-Cañamaque L, Pérez-Dueñas V, Garcerant-Tafur M, Carreras-Delgado JL. Simultaneous PET/MRI vs PET/CT in oncology. A systematic review. Rev Esp Med Nucl Imagen Mol. 2016;35(5):306–312. doi:10.1016/j.remn.2016.06.001
   PubMed Web of Science ®Google Scholar
• Kaseda K. Recent and Current Advances in FDG-PET Imaging within the Field of Clinical Oncology in NSCLC: a Review of the Literature. Diagnostics. 2020;10(8). doi:10.3390/diagnostics10080561
   Web of Science ®Google Scholar
• Kandathil A, Sibley RC III, Subramaniam RM. Lung Cancer Recurrence: (18) F-FDGPET/CT in Clinical Practice. AJR Am J Roentgenol. 2019;213(5):1136–1144. doi:10.2214/AJR.19.21227
   PubMed Web of Science ®Google Scholar
• Sarikaya I, Sarikaya A. Assessing PET Parameters in Oncologic (18) F-FDGStudies. J Nucl Med Technol. 2020;48(3):278–282. doi:10.2967/jnmt.119.236109
   PubMed Web of Science ®Google Scholar
• Pugachev A, Ruan S, Carlin S, et al. Dependence of FDG uptake on tumor microenvironment. Int J Radiat Oncol Biol Phys. 2005;62(2):545–553. doi:10.1016/j.ijrobp.2005.02.009
   PubMed Web of Science ®Google Scholar
• Ha S, Choi H, Cheon GJ, et al. Autoclustering of Non-small Cell Lung Carcinoma Subtypes on (18) F-FDGPET Using Texture Analysis: a Preliminary Result. Nucl Med Mol Imaging (2010). 2014;48(4):278–286. doi:10.1007/s13139-014-0283-3
   PubMedGoogle Scholar
• Hu WD, Wang HC, Wang YB, Cui LL, Chen XH. Correlation study on 18F-FDG PET/CT metabolic characteristics of primary lesion with clinical stage in lung cancer. Quarterly j Nuclear Med Mol Imaging. 2019;65(2):172–177. doi:10.23736/S1824-4785.19.03146-7
   PubMed Web of Science ®Google Scholar
• Honda O, Johkoh T, Sekiguchi J, et al. Doubling time of lung cancer determined using three-dimensional volumetric software: comparison of squamous cell carcinoma and adenocarcinoma. Lung Cancer. 2009;66(2):211–217. doi:10.1016/j.lungcan.2009.01.018
   PubMed Web of Science ®Google Scholar
• Choi WH, YooIe R, Kim TJ, Lee KY, Kim YK. Is the Glut expression related to FDG uptake in PET/CT of non-small cell lung cancer patients? Tech Health Care. 2015;23(Suppl 2):S311–318. doi:10.3233/THC-150967
   PubMed Web of Science ®Google Scholar
• Boellaard R, Delgado-Bolton R, Oyen WJ, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42(2):328–354. doi:10.1007/s00259-014-2961-x
   PubMed Web of Science ®Google Scholar
• Thakur MK, Gadgeel SM. Predictive and Prognostic Biomarkers in Non-Small Cell Lung Cancer. Semin Respir Crit Care Med. 2016;37(5):760–770. doi:10.1055/s-0036-1592337
   PubMed Web of Science ®Google Scholar
• Dogan I, Karyagar S, Karyagar SS, Kahraman C, Alver A. Relationship between pretreatment levels of serum Cyfra 21.1, CEA and PET metabolic parameters in NSCLC. Ann Nucl Med. 2014;28(9):829–835. doi:10.1007/s12149-014-0877-y
   PubMed Web of Science ®Google Scholar
• Nakamura K, Okumura Y, Kodama J, Hongo A, Kanazawa S, Hiramatsu Y. The predictive value of measurement of SUVmax and SCC-antigen in patients with pretreatment of primary squamous cell carcinoma of cervix. Gynecol Oncol. 2010;119(1):81–86. doi:10.1016/j.ygyno.2010.04.020
   PubMed Web of Science ®Google Scholar
• Shou H, Yasuo Y, Yuan S, Lou H, Ni J. Association of pretreatment SUV(max) of cervix and SCC-antigen with FIGO2018 stage in Stage IIB-IVB squamous cervical cancer and relationship to prognosis. Int j Gynaecol Obstetrics. 2021;152(1):112–117. doi:10.1002/ijgo.13465
   PubMed Web of Science ®Google Scholar
• Bellizzi AM. An Algorithmic Immunohistochemical Approach to Define Tumor Type and Assign Site of Origin. Adv Anat Pathol. 2020;27(3):114–163.
   PubMed Web of Science ®Google Scholar
• Osmani L, Askin F, Gabrielson E, Li QK. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): moving from targeted therapy to immunotherapy. Semin Cancer Biol. 2018;52(Pt 1):103–109. doi:10.1016/j.semcancer.2017.11.019
   PubMed Web of Science ®Google Scholar
• Kaida H, Kawahara A, Hayakawa M, et al. The difference in relationship between 18F-FDG uptake and clinicopathological factors on thyroid, esophageal, and lung cancers. Nucl Med Commun. 2014;35(1):36–43. doi:10.1097/MNM.0000000000000019
   PubMed Web of Science ®Google Scholar
• Liu LP, Zhang XX, Cui LB, et al. Preliminary comparison of diffusion-weighted MRI and PET/CT in predicting histological type and malignancy of lung cancer. Clin Respir J. 2017;11(2):151–158. doi:10.1111/crj.12316
   PubMed Web of Science ®Google Scholar
• Zeng H, Xie P, Meng X, et al. Risk factors for brain metastases after prophylactic cranial irradiation in small cell lung cancer. Sci Rep. 2017;7:42743. doi:10.1038/srep42743
   PubMed Web of Science ®Google Scholar
• Zhang Z, Wang H, Ding Q, et al. The tumor suppressor p53 regulates autophagosomal and lysosomal biogenesis in lung cancer cells by targeting transcription factor EB. Biomed Pharmacother. 2017;89:1055–1060. doi:10.1016/j.biopha.2017.02.103
   PubMed Web of Science ®Google Scholar
• Apostolova I, Ego K, Steffen IG, et al. The asphericity of the metabolic tumour volume in NSCLC: correlation with histopathology and molecular markers. Eur J Nucl Med Mol Imaging. 2016;43(13):2360–2373. doi:10.1007/s00259-016-3452-z
   PubMed Web of Science ®Google Scholar
• Li M, Liu N, Hu M, et al. Relationship between primary tumor fluorodeoxyglucose uptake and nodal or distant metastases at presentation in T1 stage non-small cell lung cancer. Lung Cancer. 2009;63(3):383–386. doi:10.1016/j.lungcan.2008.06.004
   PubMed Web of Science ®Google Scholar
• Lee P, Weerasuriya DK, Lavori PW, et al. Metabolic tumor burden predicts for disease progression and death in lung cancer. Int J Radiat Oncol Biol Phys. 2007;69(2):328–333. doi:10.1016/j.ijrobp.2007.04.036
   PubMed Web of Science ®Google Scholar
• Huang W, Fan M, Liu B, et al. Value of metabolic tumor volume on repeated 18F-FDG PET/CT for early prediction of survival in locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy. J Nucl Med. 2014;55(10):1584–1590. doi:10.2967/jnumed.114.142919
   PubMed Web of Science ®Google Scholar
• Ohri N, Duan F, Machtay M, et al. Pretreatment FDG-PET metrics in stage III non-small cell lung cancer: ACRIN 6668/RTOG 0235. J Natl Cancer Inst. 2015;107(4):djv004–djv004. doi:10.1093/jnci/djv004
   PubMedGoogle Scholar
• Dosani M, Yang R, McLay M, et al. Metabolic tumour volume is prognostic in patients with non-small-cell lung cancer treated with stereotactic ablative radiotherapy. Current Oncol. 2019;26(1):e57–e63. doi:10.3747/co.26.4167
   PubMed Web of Science ®Google Scholar